The significance of serum HBs-antigen as a monitoring examination for viral reactivation during immunesuppressive therapy in patients with previously resolved hepatitis B virus infectio
Not Applicable
- Conditions
- Collagen disease, collagen disease related disease, ulcerative colitis, Crohn's disease, intestinal Behcet's disease (simple ulcers included), psoriasis, and diseases that require other immunosuppressive therapies.
- Registration Number
- JPRN-UMIN000020029
- Lead Sponsor
- Saitama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
Not provided
Exclusion Criteria
Patients tested positive for serum HBs-antigen Patients receiving an HBs-antigen vaccination
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Both serum HBs-antigen and HBV-DNA are monitored repeatedly every 1 to 3 months during immunosuppressive therapies, and development of de novo HBV hepatitis is evaluated until 12 months after initiation of the therapies.
- Secondary Outcome Measures
Name Time Method